在绝经后期女性中, 一种新的非激素药丸将热潮切除74%, 但食品药品管理局尚未批准。 A new non-hormonal pill cut hot flashes by 74% in postmenopausal women, but the FDA hasn't approved it yet.

根据JAMA内科医学研究,在北美和欧洲313名参与者中,一种非激素药丸,elinzanetant,在三个月内,在绝经后的妇女中,减少了近74%的发热和夜间出汗. An experimental non-hormonal pill, elinzanetant, reduced hot flashes and night sweats by nearly 74% in postmenopausal women over three months, according to a JAMA Internal Medicine study of 313 participants across North America and Europe. 120毫克每日剂量针对温度调控中涉及的大脑受体,提供无雌激素的缓解,不同于具有中风和癌症等风险的荷尔蒙疗法。 The 120 mg daily dose targeted brain receptors involved in temperature regulation, offering relief without estrogen, unlike hormone therapy which carries risks like stroke and cancer. 津贴持续到一年,对肝脏或骨骼健康没有伤害。 Benefits lasted up to a year with no harm to liver or bone health. 副作用包括睡不着、疲劳和头痛。 Side effects included sleepiness, fatigue, and headache. 虽然睡眠和生活质量得到改善,但结果在统计上并不显著。 While sleep and quality of life improved, results weren’t statistically significant. 美国食品药品管理局推迟批准, The FDA has delayed approval, requesting more review. 该药物由Bayer研制,由该公司出资,可以为妇女提供安全选择,包括乳腺癌患者。 The drug, developed by Bayer and funded by the company, may provide a safe option for women, including those with breast cancer.